Sveinn Sölvason, President and CEO, comments:

"Sales in Q2 2025 amounted to USD 232 million and reported growth was 7% of which 5% was organic.

Growth was strong in our Prosthetics & Neuro Orthotics segment, mainly driven by the continued strong momentum in EMEA supported by solid contribution from our recently launched innovation.

The EBITDA margin was strong at 21% in Q2 2025. The margin benefited positively from strong sales in Prosthetics & Neuro Orthotics, solid efficiency in manufacturing, and continued strong cost control in SG&A."

Embla will host a conference call on July 22, 2025 at 09:00 CET / 7:00 GMT / 3:00 EST.

A webcast will be available through the following link: Embla Medical Q2 2025 webcast

To participate in the telephone conference please use the dial-in details provided below:
DK: +45 78 76 84 90
SE: +46 31-311 50 03
UK: +44 20 3769 6819
US: +1 646 787 0157
Participant access code: 274982

• Download Company Announcement
• Download Investor Presentation